Literature DB >> 29122763

Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas.

Y W Park1,2, K Han2, S S Ahn3, S Bae2, Y S Choi2, J H Chang4, S H Kim5, S-G Kang4, S-K Lee2.   

Abstract

BACKGROUND AND
PURPOSE: WHO grade II gliomas are divided into three classes: isocitrate dehydrogenase (IDH)-wildtype, IDH-mutant and no 1p/19q codeletion, and IDH-mutant and 1p/19q-codeleted. Different molecular subtypes have been reported to have prognostic differences and different chemosensitivity. Our aim was to evaluate the predictive value of imaging phenotypes assessed with the Visually AcceSAble Rembrandt Images lexicon for molecular classification of lower grade gliomas.
MATERIALS AND METHODS: MR imaging scans of 175 patients with lower grade gliomas with known IDH1 mutation and 1p/19q-codeletion status were included (78 grade II and 97 grade III) in the discovery set. MR imaging features were reviewed by using Visually AcceSAble Rembrandt Images (VASARI); their associations with molecular markers were assessed. The predictive power of imaging features for IDH1-wild type tumors was evaluated using the Least Absolute Shrinkage and Selection Operator. We tested the model in a validation set (40 subjects).
RESULTS: Various imaging features were significantly different according to IDH1 mutation. Nonlobar location, larger proportion of enhancing tumors, multifocal/multicentric distribution, and poor definition of nonenhancing margins were independent predictors of an IDH1 wild type according to the Least Absolute Shrinkage and Selection Operator. The areas under the curve for the prediction model were 0.859 and 0.778 in the discovery and validation sets, respectively. The IDH1-mutant, 1p/19q-codeleted group frequently had mixed/restricted diffusion characteristics and showed more pial invasion compared with the IDH1-mutant, no codeletion group.
CONCLUSIONS: Preoperative MR imaging phenotypes are different according to the molecular markers of lower grade gliomas, and they may be helpful in predicting the IDH1-mutation status.
© 2018 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29122763     DOI: 10.3174/ajnr.A5421

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  31 in total

1.  Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.

Authors:  P Darvishi; P P Batchala; J T Patrie; L M Poisson; M-B Lopes; R Jain; C E Fadul; D Schiff; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-23       Impact factor: 3.825

2.  Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas.

Authors:  Shuang Wu; Jin Meng; Qi Yu; Ping Li; Shen Fu
Journal:  J Cancer Res Clin Oncol       Date:  2019-02-04       Impact factor: 4.553

3.  Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma.

Authors:  Niha Beig; Salendra Singh; Kaustav Bera; Prateek Prasanna; Gagandeep Singh; Jonathan Chen; Anas Saeed Bamashmos; Addison Barnett; Kyle Hunter; Volodymyr Statsevych; Virginia B Hill; Vinay Varadan; Anant Madabhushi; Manmeet S Ahluwalia; Pallavi Tiwari
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

4.  Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review.

Authors:  Arian Lasocki; Mustafa Anjari; Suna Ӧrs Kokurcan; Stefanie C Thust
Journal:  Neuroradiology       Date:  2020-08-25       Impact factor: 2.804

Review 5.  Precision Digital Oncology: Emerging Role of Radiomics-based Biomarkers and Artificial Intelligence for Advanced Imaging and Characterization of Brain Tumors.

Authors:  Reza Forghani
Journal:  Radiol Imaging Cancer       Date:  2020-07-31

6.  A 1p/19q Codeletion-Associated Immune Signature for Predicting Lower Grade Glioma Prognosis.

Authors:  Jie Xu; Fang Liu; Yuntao Li; Liang Shen
Journal:  Cell Mol Neurobiol       Date:  2020-09-07       Impact factor: 5.046

7.  "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.

Authors:  Rajan Jain; Derek R Johnson; Sohil H Patel; Mauricio Castillo; Marion Smits; Martin J van den Bent; Andrew S Chi; Daniel P Cahill
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

8.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

9.  Machine learning-based quantitative texture analysis of conventional MRI combined with ADC maps for assessment of IDH1 mutation in high-grade gliomas.

Authors:  Deniz Alis; Omer Bagcilar; Yeseren Deniz Senli; Mert Yergin; Cihan Isler; Naci Kocer; Civan Islak; Osman Kizilkilic
Journal:  Jpn J Radiol       Date:  2019-11-18       Impact factor: 2.374

10.  Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.

Authors:  Maike Kern; Timo A Auer; Uli Fehrenbach; Yasemin Tanyildizi; Thomas Picht; Martin Misch; Edzard Wiener
Journal:  Neuroradiol J       Date:  2020-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.